News

Suresh A. Ramalingam, MD,&nbsp;discusses some of the changes to the NCCN guidelines in NSCLC, specifically with <em>EGFR</em>-mutation&ndash;positive disease, and how the frontline recommendation of osimertinib will impact clinical practice.

George R. Blumenschein, MD,&nbsp;discusses the current treatment landscape for patients with squamous cell lung cancer.

Richard S. Finn, MD, highlights the evolution of CDK 4/6 inhibition in the field of breast cancer and appropriate patient selection for this type of therapy.

Ribociclib (Kisqali) met its primary endpoint for progression-free survival (PFS) in premenopausal women with&nbsp;hormone-receptor (HR)&ndash;positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer, according to topline results from the MONALEESA-7 trial, Novartis recently announced in a press release.

Three members will lead the American Society of Hematology (ASH) Executive Committee with terms beginning after the 2017 ASH Annual Meeting, which will be held December 9 to 12 in Atlanta, Georgia: Stephanie Lee, MD; Agnes Lee, MD; and Joseph Mikhael, MD.

In data presented at the 2017 ESMO Asia Congress, updated results again sustained the benefit of frontline osimertinib (Tagrisso) in patients with <em>EGFR</em>-positive advanced non&ndash;small cell lung cancer (NSCLC) and CNS metastases at baseline.

After granting a priority review to durvalumab (Imfinzi) in October for the treatment of patients&nbsp;with stage III, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation, the FDA is now reviewing results from the phase III PACIFIC trial, which have now&nbsp;been published in the print edition of the New England Journal Medicine.

Nilotinib (Tasigna) has been approved by the FDA for the treatment of pediatric patients with&nbsp;Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The approval is both in the frontline setting and for those with&nbsp;resistance or intolerance to prior therapy, including imatinib.

In topline results announced from the phase III IMpower150 trial, atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) and chemotherapy delayed progression or death when compared with bevacizumab and chemotherapy alone for patients with advanced nonsquamous non&ndash;small cell lung cancer.

Sunitinib (Sutent) has been granted FDA approval for the adjuvant treatment of patients with renal cell carcinoma (RCC) who&nbsp;have received nephrectomy and are high risk for recurrence.

The FDA has approved the IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets)&nbsp;tumor profiling assay, an in vitro diagnostic test that can identify more tumor biomarkers than any test previously reviewed by the agency.

The anti&ndash;B-cell maturation antigen chimeric antigen receptor T-cell therapy&nbsp;bb2121 has been granted a breakthrough therapy designation by the FDA for previously treated patients with relapsed/refractory multiple myeloma.

According to results reported&nbsp;at the 2017 international meeting of the European Society of Gynaecological Oncology (ESGO 20), maintenance therapy with olaparib monotherapy was safe and provided clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer.

PARP inhibitors offer great potential to improve outcomes for patients with ovarian cancer, and evidence will hopefully support their use in the first-line management of these patients,&nbsp;said Susana M. Campos, MD, a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School, during her talk at the 35th annual CFS^&reg; meeting.

Richard Kim, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic colorectal cancer, including the role of mutation testing and location of the tumor. Kim, associate professor of oncology, Moffitt Cancer Center, explained his treatment decisions based on 2 case scenarios during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

Obinutuzumab (Gazyva) has been approved by the FDA in combination with chemotherapy, followed by&nbsp;obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma,&nbsp;according to Genentech, the manufacturer of the therapy.

Adam Waxman, MD,&nbsp;discusses emerging regimens for patients with multiple myeloma.<br /> &nbsp;

Progression-free survival was extended by 3.6 months with higher-dose, once-weekly carfilzomib (Kyprolis) compared with a lower-dose, twice-weekly regimen in patients with relapsed/refractory multiple myeloma, according to&nbsp;according to phase III results from the ARROW trial.

Understanding genetic abnormalities is key to better improving outcomes in multiple myeloma, particularly for high-risk patients, Shaji K. Kumar, MD, said in his talk at the&nbsp;35th annual CFS.

Mike Cusnir, MD, co-director of gastrointestinal malignancies, Mount Sinai Medical Center, recently discussed the cases of 2 patients with metastatic colorectal cancer (mCRC).<br /> &nbsp;

Fulvestrant (Faslodex) has been approved by the FDA for use in combination with the CDK4/6 inhibitor abemaciclib (Verzenio) as a treatment for patients with HR+/HER2- advanced or metastatic breast cancer who have progressed after endocrine therapy.

According to results from the phase III phase III LyMa trial published in the <em>New England Journal of Medicine, </em>survival was improved for patients with mantle cell lymphoma with maintenance&nbsp;rituximab (Rituxan) following autologous stem-cell transplantation (ASCT).

Andre Goy, MD,&nbsp;discusses the excitement surrounding novel therapies on the horizon in mantle cell lymphoma, as well as how the treatment paradigm will shift in the next 5 to 10 years.

In an effort to improve bladder preservation and quality of life, investigators are currently exploring the efficacy of risk-adapted treatment for patients with muscle-invasive bladder cancer&nbsp;after receiving a neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) regimen.

The use of atezolizumab (Tecentriq) is being recommended by the UK&#39;s National Institute for Health and Care Excellence (NICE) for treatment-na&iuml;ve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.

Combining the PD-1 inhibitor nivolumab (Opdivo) with the novel IDO inhibitor&nbsp;BMS-986205 generated promising response rates&nbsp;in patients with advanced cervical or bladder cancers and similar adverse effects to what is seen with anti&ndash;PD-1 monotherapy, according to findings of an early-phase clinical trial presented by Jason J. Luke, MD, during the&nbsp;SITC 32nd Annual Meeting.

Hans-Joachim Schmoll, MD, discusses&nbsp;updated CHARTA findings, the current role of chemotherapy in patients with metastatic CRC, and his predictions for the future CRC treatment landscape.

Cathy Eng, MD, discussed optimizing sequencing beyond disease progression in CRC

Johanna Bendell, MD, discusses&nbsp; the current and emerging treatment landscape of immunotherapy for patients with CRC.

In a presentation at the&nbsp;35th annual CFS, Edward S. Kim, MD, discussed the &quot;renaissance&quot; in the&nbsp;non&ndash;small cell lung cancer landscape that has come with the rapid evolution of targeted treatment for patients with&nbsp;<em>EGFR</em>-mutation&ndash;positive disease.